Collectively, these results open exciting new avenues to use STMN2 and UNC13A as potential therapeutic targets in a broad range of neurodegenerative conditions with TDP-43 proteinopathy including Alzheimer’s disease. Here, STMN2 is linked to early-onset autosomal dominant Alzheimer disease.